The Caledonian-Record

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for ...
The Business Journals

Replimune plans third attempt at RP1 approval in coming days

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Replimune received rejections in ...
Seeking Alpha

Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...